Hrs-4729

Phase 1

FFujian Shengdi Pharmaceutical Co., Ltd.

Hrs-4729 is one of 2 therapeutic programs targeting Overweight/Obesity. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Overweight/obesityRecruiting

Overweight/obesityPhase 1

Recruiting

Competition

Competitive Landscape

1 competitor in Overweight/obesity

#DrugCompanyPhaseTrials

BGM0504

BBrightGene Bio-Medical Technology Co., Ltd.

Phase 1

—2

Hrs-4729

FFujian Shengdi Pharmaceutical Co., Ltd.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Overweight/obesity

NCT07807059

Clinical

Trials by Indication[1]

Overweight/Obesity1 trial

An Open-Label, Parallel-Group, Single-Dose Pharmacokinetic Study of HRS-4729 Injection in Healthy Participants and Patients With Renal Impairment

Recruiting·FFujian Shengdi Pharmaceutical Co., Ltd.·Phase 1·NCT07807059·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Hrs-4729. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Hrs-4729. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Fujian Shengdi Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: FFujian Shengdi Pharmaceutical Co., Ltd.

Hrs-4729

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Overweight/Obesity1 trial

References

Drug Info

Quick Facts

Related News